AC
CRL icon

Armistice Capital’s Charles River Laboratories CRL Stock Holding History

Armistice Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,932
Closed -$302K – 397
2025
Q3 		$302K Buy
+1,932
New +$307K ﹤0.01% 246
2024
Q3 		– Sell
-119,071
Closed -$24.6M – 275
2024
Q2 		$24.6M Buy
119,071
+49,189
+70% +$11.1M 0.31% 57
2024
Q1 		$18.9M Buy
69,882
+33,882
+94% +$8.09M 0.25% 70
2023
Q4 		$8.51M Sell
36,000
-120,000
-77% -$23.6M 0.12% 100
2023
Q3 		$30.6M Buy
+156,000
New +$32M 0.47% 43

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Armistice Capital's CRL Position: Q4 2025 in Review

Armistice Capital sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 1,932 shares — an estimated $302K sold.

Armistice Capital first reported a position in CRL in Q3 2023 and held it in 5 quarters. The position peaked at $30.6M in Q3 2023. 580 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Armistice Capital reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Armistice Capital sold 1,932 Charles River Laboratories shares in Q4 2025, an estimated $302K.
  • Armistice Capital first reported a position in Charles River Laboratories in Q3 2023 and held it in 5 quarters.
  • Armistice Capital's Charles River Laboratories position peaked at $30.6M in Q3 2023.
  • 580 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.